FTC challenges patents on 20 brand-name drugs, including Ozempic, to spur competition and lower drug prices.

The FTC is challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, aiming to spur competition and lower drug prices. The agency alleges that drugmakers have filed inaccurate or misleading patents to keep generic competitors from entering the market, resulting in artificially high drug prices. In response, the FTC sent warning letters to 10 drugmakers, such as Novo Nordisk, GlaxoSmithKline, and AstraZeneca.